Navigate to
-
Please enter a valid video URL. The URL can point to any video file or a Youtube video. Please enter a valid video URL. The URL can point to any video file or a Youtube video. Reimagine a PBM with...
-
April 14, 2025 Author: Simone Ndujiuba, PharmD, BCOP In the United States, pancreatic cancer is the fourth leading cause of cancer related death.¹ In 2023, approximately 64,050 people were...
-
References Sadelain M. Engineering the future – innovation in CAR T therapy design. Presented at Precision Medicine World Conference. March 4, 2026: Santa Clara, CA. Harris E, June C, Sadelain M....
-
Clinical Solutions Vice President (Remote) Job description: The Medicare Part D pharmacy programs manager manages the coordination of benefits in the pharmacy program with Medicare Part D plans,...
-
Prime Therapeutics’ newest Clinical Insights explores emerging evidence and innovations influencing treatment strategies and shaping healthcare decision-making
Prime Article: Stories -
High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...
-
NCCN Recommendations for use of immunoglobulin² Intervention CAR T BsAbs Other indications Immunoglobulin replacement After CAR T-cell therapy, regular immune globulin infusions based on clinical...
-
Integrated support for patients with cystic fibrosis drives down cost, improves medication adherence
Prime’s IntegratedRx® – Cystic Fibrosis product earns 94% member satisfaction rate
Prime Article: Stories -
FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...
-
Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...
-
Oral selective estrogen receptor degraders Agent Status and key trial data What to watch Elacestrant (Orserdu) Approved in 2023 as the first oral SERD in ESR1-mutant metastatic breast cancer via...
-
Tab 1 BEHAVIORAL HEALTH CORNER WEIGHT MANAGEMENT CORNER Clinical News EDITOR-IN-CHIEF: Maryam Tabatabai, PharmD EXECUTIVE EDITOR: Anna Schreck Bird, PharmD DEPUTY EDITORS: Erik Hamel, PharmD;...
-
Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...
-
Greg Myers, vice president of AI strategy at Prime Therapeutics, shares how AI is creating value for healthcare payers — and what it takes to scale it responsibly
Prime Article: Stories -
The CDC is reporting influenza-like illness (ILI) for the week ending March 15, 2025 (week 11). Seasonal influenza activity remains increased across the U.S. but has decreased for five consecutive...
-
While AI has helped streamline many processes, its ultimate impact may be debatable at this point, and caution in certain areas is warranted, according to some industry experts
Prime Article: In the News -
Edwards joins as president, markets.
Prime Article: Press Releases -
Health care consulting and technology organization awarded 2025 All-Star Awards to nine Prime employees
Prime Article: Stories -
Designation demonstrates highest level of commitment to quality health care
Prime Article: Press Releases -
Designation demonstrates highest level of commitment to quality health care.
Prime Article: Press Releases